Equillium (EQ) vs Lifevantage (LFVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Equillium (EQ) has outperformed Lifevantage (LFVN) over the past year, losing 18.5% versus a loss of 31.9%. Over five years, LFVN leads with a -11.8% price change compared with -79.7% for EQ. Lifevantage is the larger company by market cap ($75.5 million vs $75.5 million), about 1.0 times the size.
Lifevantage pays a dividend yielding 3.08%, while Equillium does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EQ | LFVN |
|---|---|---|
| Share price | $1.19 | $6.00 |
| Market cap | $75.46M | $75.54M |
| 1-day change | -9.85% | 0.00% |
| YTD return | -23.23% | -2.60% |
| 1-year return | -18.49% | -31.90% |
| 5-year return | -79.69% | -11.76% |
| P/E ratio (TTM) | — | 15.00 |
| Forward P/E | — | 15.52 |
| EPS (TTM) | $-0.14 | $0.40 |
| Dividend yield | 0.00% | 3.08% |
| Annual dividend | $0.00 | $0.185 |
| Revenue (latest FY) | — | $182.59M |
| Revenue growth (YoY) | — | -20.10% |
| Net income (latest FY) | $-22.40M | $5.07M |
| Gross margin | — | 77.56% |
| Operating margin | — | 3.34% |
| Net margin | — | 2.78% |
| 52-week high | $3.54 | $11.71 |
| 52-week low | $0.76 | $3.90 |
| Distance from 52-week high | -66.38% | -48.76% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +619.33% | +25.00% |
| Average volume | 547.91K | 48.46K |
| Shares outstanding | 63.41M | 12.59M |
| Employees | 14 | 209 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EQ has outperformed LFVN by 13.4 percentage points over the past year.
- Lifevantage offers a meaningfully higher dividend yield (3.08% vs 0.00%).
About Equillium
EQ stock →Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About Lifevantage
LFVN stock →LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, gut health, and skin and hair care products in the United States and internationally. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; LifeVantage Daily Wellness, a dietary supplement to strengthen immune health; LifeVantage Rise AM and Reset PM System that provides the body with the right nutrients; LifeVantage D3+, a dietary supplement that provides vitamin D3 and K2, magnesium, calcium, and other trace minerals to support a balanced immune system, strong bones, and cardiovascular health; P84 System, a product activator consisting of PhytoPower 1 and PhytoPower 2 that contains probiotics, prebiotics, postbiotics, digestive enzymes, and superfood blends designed to support gut health; MindBody GLP-1 System, a dietary supplement that combines two products, MB Core and MB Enhance, which are designed to support weight management and wellness by activating GLP-1 naturally and balancing signals along the gut-brain axis; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.
Health Care · Biotechnology: Pharmaceutical Preparations · 209 employees
EQ vs LFVN FAQ
Which is bigger, Equillium or Lifevantage?
Lifevantage (LFVN) is larger, with a market capitalization of $75.54M compared with $75.46M for Equillium (EQ).
Which stock has performed better over the past year, EQ or LFVN?
EQ returned -18.49% over the past 12 months, compared with -31.90% for LFVN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Equillium or Lifevantage?
Lifevantage pays a dividend yielding 3.08%, while Equillium does not currently pay a regular dividend.
Are Equillium and Lifevantage in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.